Optimistic Outlook for BioRestorative Therapies Backed by Clinical and Strategic Advances

Maxim Group analyst Michael Okunewitch has maintained their bullish stance on BRTX stock, giving a Buy rating yesterday.

Michael Okunewitch’s rating is based on a mixture of BioRestorative Therapies’ recent progress in its clinical trial and the unique characteristics of its product, BRTX-100. Despite the financial results showing a net loss, the company appears to be adequately funded for the near future, thanks to a successful warrant inducement. Importantly, an amendment to the ongoing Phase 2 study protocol has been approved, which is expected to improve the reliability of the trial results by introducing a sham procedure as the control rather than a saline injection, which can potentially provide therapeutic benefit itself. This change may increase the likelihood of demonstrating the efficacy of BRTX-100, which is a key factor in Okunewitch’s optimistic outlook.

Additionally, the therapeutic product BRTX-100 has distinguishing features that may offer advantages over existing therapies. It is an autologous mesenchymal stem cell therapy that is cultured under hypoxic conditions, potentially enhancing cell survival in low-oxygen environments such as those found in degenerative diseases. This could lead to a more potent and differentiated therapy. Moreover, the significant need for effective treatments in chronic lower back pain (CLBP) and the partial de-risking of BioRestorative’s program based on previous data from a similar therapy further solidify the rationale for a Buy rating. The ongoing Phase 2 trial is proceeding with accelerated enrollment, which may lead to early indicators of efficacy and act as a catalyst for the company’s stock value.

In another report released yesterday, Roth MKM also maintained a Buy rating on the stock with a $15.00 price target.

Based on the recent corporate insider activity of 15 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of BRTX in relation to earlier this year.

TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.

BioRestorative Therapies (BRTX) Company Description:

Biorestorative Therapies Inc. provides stem cell collections, storage, and treatment services. It intends to develop a laboratory, performing cellular characterization and culturing, therapeutic outcomes analysis, stem cell-related IP and stem cell collection and storage services. The company is developing the following scientific initiatives: brtxDISC Program offers a non-surgical treatment for bulging and herniated discs and addresses the gap between non-invasive and invasive back procedures. The ThermoStem Program focuses on treatments for metabolic disorders and obesity and uses brown fat stem cells, which initial research indicates increased caloric burning and reduced glucose and lipid levels in the body. It also offers plant stem cell-based facial creams and products under the Stem Pearls brand. Biorestorative Therapies was founded on June 13, 1997 and is headquartered in Melville, NY.